Table S1. The number of unique and total peptides for the supernatant of CdM\textsuperscript{CRTL} and CdM\textsuperscript{SORA} via LC-MS/MS analysis

| Accession | Description | # unique peptides | # total peptides | # unique Peptides + sorafenib | # total Peptides + sorafenib |
|-----------|-------------|-------------------|------------------|-------------------------------|-------------------------------|
| P07355    | ANXA2       | 1                 | 1                | 15                            | 15                            |
| P00558    | PGK1        | 0                 | 0                | 9                             | 9                             |
| P09211    | GSTP1       | 2                 | 2                | 9                             | 9                             |
| P04083    | ANXA1       | 1                 | 1                | 8                             | 8                             |
| P28482    | MAPK1       | 0                 | 0                | 8                             | 10                            |
| P09429    | HMGB1       | 1                 | 1                | 4                             | 5                             |
| Q01469    | FABP5       | 0                 | 0                | 4                             | 4                             |
| P0DP23    | CALM1       | 0                 | 0                | 4                             | 4                             |
| P07339    | CTSD        | 0                 | 0                | 4                             | 4                             |
| P08758    | ANXA5       | 1                 | 1                | 4                             | 5                             |
| Q99075    | HBEGF       | 0                 | 0                | 4                             | 4                             |
| Q9UQ80    | PA2G4       | 0                 | 0                | 3                             | 3                             |
| Q9Y376    | CAB39       | 0                 | 0                | 3                             | 3                             |
| Q16270    | IGFBP7      | 10                | 10               | 2                             | 2                             |
| Q9Y5Z4    | HEBP2       | 0                 | 0                | 2                             | 2                             |
| P18065    | IGFBP2      | 0                 | 0                | 1                             | 1                             |
| Q04756    | HGFAC       | 0                 | 0                | 1                             | 1                             |

Abbreviation: CRTL, control; SORA, sorafenib; CdM, HUVECs conditional medium.